Shifting models in life science partnering

October 28, 2014 p360

Picture1Ahead of BIO-Europe®, Susan Herbert, Executive VP for Global Business Development and Alliance Management at Merck Serono, sat down with our Insight team to discuss the new, evolving landscape that is partnering in the industry.

Shifts include better communication and working with companies that molecules are licensed from and fully taking advantage of the knowledge that company has of the molecule. Merck Serono is also working to be nimble – identifying and moving quickly on deals that are ideal for their portfolio.

Read the full article here.

How have you seen life science partnering change over the last few years?  What’s the main trend you’ve identified?

Merck Serono is just one of 1,841 companies joining us next week in Frankfurt. Are you looking for your next partner? Register to join us November 3-5 at BIO-Europe.

Previous Article
#BEU14: Funding in Europe and deals to change business
#BEU14: Funding in Europe and deals to change business

On Day Two of BIO-Europe®, we looked at how deal makers spend their days, funding for small and midsized Eu...

Next Article
Due diligence: How to ensure a successful process
Due diligence: How to ensure a successful process

It is largely accepted that the biggest challenges for life science companies in completing M&A or partneri...